DrugPatentWatch Database Preview

Litigation Details for Procter & Gamble Co. v. Teva Pharmaceuticals (D. Del. 2004)

« Back to Dashboard

Procter & Gamble Co. v. Teva Pharmaceuticals (D. Del. 2004)

Docket		Date Filed	2004-08-13
Court	District Court, D. Delaware	Date Terminated	2008-05-23
Cause	35:271 Patent Infringement	Assigned To	Joseph James Farnan Jr.
Jury Demand	None	Referred To
Parties	TEVA PHARMACEUTICALS U.S.A., INC.; THE PROCTER & GAMBLE COMPANY
Patents	3,591,584; 4,072,746; 4,444,779; 4,621,077; 4,687,777; 5,358,941; 5,622,721; 5,681,590; 5,804,570; 5,994,329; 6,015,801; 6,090,410; 6,096,342; 6,165,513; 6,194,004; 6,465,443
Link to Docket	External link to docket

Details for Procter & Gamble Co. v. Teva Pharmaceuticals (D. Del. 2004)

Date Filed	Document No.	Description	Snippet	Link To Document
2006-12-20	100	POST Trial Brief	;s:766:	External link to document
2007-07-06	107	Exhibit	t.|iSt F’atent l\lo" 4,444,779 (the “'779 Patent”)r The ’779 patent is of particular relevance…ciaimed in the patent in suit Takeda owns U.S, Patent 4,687,777 (the "’?'77 patent") entitled… ’779 patent That patent covers a subset of compounds originally included in the '200 patent application… is not patentable fm D. “if the differences between the subject matter sought to be patented and the …court Hrst considered Takeda’s U.S. Patent 4,287,200 (the “'200 patent"), which was issued on Septernber	External link to document
2008-02-28	117	Opinion	infringed on United States Patent Nos. 5,538,122 (“the ‘122 Patent”) and 6,096,342.l (D.I. l.) On August 25…the ‘406 patent, and in particular, claim 15 of the ‘406 patent. (Teva PFF 15.) The ‘406 Patent issued …between the ‘406 Patent and ‘122 Patent, and whether such differences render the ‘122 patent obvious. The …matter claimed by the ‘122 patent and the ‘406 patent. For example, the ‘122 patent discloses the design and…double patenting. Obviousness-type double patenting, also known as non-statutory double patenting, is a	External link to document
2008-05-27	127	Patent/Trademark Report to Commissioner	Attached Order of Final Judgment (*Please note Patent No. 6,096,342 was omitted from the Amended Complaint, …5,583,122 12/10/1996 Procter & Gamble Company 2 6,096,342* 8/1/2000 Procter & Gamble Company 3 4 5 ln…Pharmaceuticals PATENT OR DATE OF PATENT TRADEMARK NO' OR TRADEMARK HOLDER OF PATENT OR TRADEMARK l…I Other Pleading PATENT OR DATE OF PATENT TRADEMARK NO_ OR TRADEMARK HOLDER OF PATENT OR TRADEMARK 1 2… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,583,122; (Attachments	External link to document
2005-03-08	16	MEMORANDUM in Support	Action No. 04-939: U.S. Patents 5,994,329, 6,432,932, and 6,465,443. These patents include claims for once-weekly…the patents listed in the FDA’s “Orange Book” in connection With that drug, or that those patents are …of bone. The patents listed in the Orange Book for Actonel include P&G’s U.S. Patent 5,583,l22, Which…addition to the ’ 122 patent, the Orange Book also lists for Actonel three patents belonging to Merck, …cases the patents claim risedronate or its use. P&G has a legal interest in all the patents in both	External link to document
2005-03-08	17	Notice (Other)	Prosecution histories for U.S. Patent Nos. 5,583,122, 5,994,329, 6,432,932, and 6,465,443, including lnterference…lnterference 102,399. U.S. Patent Nos. 5,730,715, 5,869,471, 4,761,406, 4,416,877, and 3,400,150. Tang et al… 2004 23 May 2008 1:04-cv-00940-JJF Patent None District Court, D. Delaware	External link to document
2005-03-15	18	Exhibit A - E	811986 Blum ctnl. 4- 514¢'107 [51] ADSTRACT 4,621,077 1111935 Rusinietzl!.\ 514{}03 4,637,'167 811987…DOCUNHENTS '$,4?5,339 A '[/1984 Pilnhfnrd 4,621,077 A nam koszni er nl_ 4,761,406 A moss mm er .1!…United States Patent Daifotis et al. Filed 03/15/2005 (10) Patent No.: (45) Date of patent: US 6,465,…-2 United States Patent Filed 03/15/2005 (3.2) (10) Patent No.: US 6,432,932…infringement oi" limited States Patent NO 6,720,488 (" '488 patent"), which is not at issue	External link to document